HRMY
Harmony Biosciences Holdings Inc

17,090
Mkt Cap
$1.74B
Volume
933,541.00
52W High
$41.61
52W Low
$25.52
PE Ratio
9.75
HRMY Fundamentals
Price
$30.25
Prev Close
$29.60
Open
$29.73
50D MA
$31.44
Beta
0.82
Avg. Volume
1.06M
EPS (Annual)
$2.51
P/B
2.25
Rev/Employee
$2.67M
Loading...
Loading...
News
all
press releases
Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last?
Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?
Stocktwits·3d ago
News Placeholder
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX (pitolisant) franchise delivered net revenue of approximately...
Business Wire·3d ago
News Placeholder
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -22.62% and -57.71%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Zacks·1mo ago
News Placeholder
Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study
The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.
Stocktwits·1mo ago
News Placeholder
Can Cannabis Stocks Reverse Their Prolonged Downtrend?
Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.
Zacks·3mo ago
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -12.82% and -1.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago

Latest HRMY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.